Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
  2. News & Events
  3. Press releases
  4. Press releases

Press releases

  • 20 May 2019

    ORYZON Receives $1.5 million grant from Alzheimer’s Drug Discovery Foundation (ADDF)

  • 13 May 2019

    ORYZON Reports Financial Results and Corporate Update for the 1st Quarter, 2019

  • 6 May 2019

    Oryzon to present at upcoming international conferences

  • 25 April 2019

    ORYZON to present vafidemstat efficacy data at the 7th World Congress on ADHD in Lisbon

  • 15 April 2019

    ORYZON to present further REIMAGINE efficacy data with vafidemstat at the 7th World Congress on ADHD in Lisbon

  • 8 April 2019

    ORYZON to present first in human efficacy data with Vafidemstat at the 27th European Congress of Psychiatry in Warsaw

  • 5 April 2019

    Oryzon to present at upcoming international conferences

  • 25 March 2019

    Oryzon to present at upcoming international conferences

  • 20 March 2019

    Oryzon to present latest advances of Vafidemstat at Oppenheimer’s 29th Annual Healthcare Conference

  • 11 March 2019

    ORYZON announces FDA Approval of IND for ETHERAL, a Phase IIa trial of the epigenetic drug Vafidemstat in Patients with mild to moderate Alzheimer’s disease

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 1
  • Page 2
  • Current page 3
  • Page 4
  • Next page Next ›
  • Last page Last »

Email alerts

Subscribe and stay up to date with our latest news

Subscribe
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel